PEGylated soluble tumor necrosis factor receptor I

Known as: PEG sTNFRI, Pegsunercept 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2008
01220022008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
The objective of the study was to evaluate synovial tissue receptor activator of nuclear factor-κβ ligand (RANKL) and… (More)
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Retinal microvascular cell loss plays a critical role in the pathogenesis of diabetic retinopathy. To examine this further, type… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Preclinical studies have indicated that pegsunercept, a polyethylene-glycol-modified soluble tumor-necrosis-factor receptor type… (More)
Is this relevant?
2006
2006
Preclinical studies have indicated that pegsunercept, a polyethylene-glycol-modified soluble tumor-necrosis-factor receptor type… (More)
Is this relevant?
2006
2006
Preclinical studies have indicated that pegsunercept, a polyethylene-glycol-modified soluble tumor-necrosis-factor receptor type… (More)
Is this relevant?
2005
2005
OBJECTIVE To investigate whether the bone-preserving effects of a RANKL antagonist or a tumor necrosis factor (TNF) antagonist… (More)
Is this relevant?
2005
2005
OBJECTIVE In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I… (More)
Is this relevant?
2002
2002
OBJECTIVE To assess the capacities of the cytokine inhibitors interleukin-1 receptor antagonist (IL-1Ra; anakinra) and PEGylated… (More)
Is this relevant?